ArticleFrontiers in cell and developmental biology2026
Stem cell therapy targets THBS1 to reverse endometrial fibrosis.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Hydrogels for Intrauterine Adhesion Therapy and Endometrial Regeneration.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrauterine adhesions (IUA) are a major cause of female infertility and recurrent pregnancy loss, characterized by endometrial fibrosis. The molecular mechanisms underlying IUA fibrosis are poorly understood. Thrombospondin-1 (THBS1), a matricellular protein linked to fibrotic disorders, has not been extensively studied in IUA. This study investigates the role of THBS1 in IUA pathogenesis and the therapeutic potential of decidua-derived mesenchymal stem cells (DMSCs), focusing on the PI3K/AKT signaling pathway. Methods: Transcriptomic profiling identified significant upregulation of THBS1 in IUA tissues. Pathway analysis suggested that THBS1 promotes fibrosis via the PI3K/AKT pathway. Results: THBS1 silencing reduced fibrotic markers and inhibited PI3K/AKT pathway activation Conclusion: THBS1 is a key pro-fibrotic factor in IUA, modulating the PI3K/AKT pathway. DMSCs effectively mitigate fibrosis and promote endometrial regeneration, potentially by downregulating THBS1. This study highlights THBS1 as a promising therapeutic target and reinforces the clinical potential of DMSCs for IUA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.